Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Donald Seaton, James Garner, Fraser Logue

Premium

Integrated Diagnostics announced this week the appointment of Donald Seaton as its chief financial officer and James Garner as its chief business officer.

Seaton brings to the company more than two decades of experience as a biotech executive and was previously the chief financial officer and chief operating officer at EndoGastric Solutions. Garner, meanwhile, has been consulting Integrated Diagnostics for more than a year. Prior to joining the company, Garner was senior VP of global sales and i3 research at UnitedHealth Group.

With these appointments, Integrated Diagnostics has fully formed its executive team, the company said.


UK-based Lab21 has appointed Fraser Logue as the company's group director of quality, regulatory affairs and operations excellence. Previously, Logue worked within various divisions of Abbott Laboratories. Most recently, he was division VP of worldwide manufacturing of Abbott's diabetes care division.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.